Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Improved Remission in Older People with AML

JAMA Oncol; ePub 2017 Sep 14; Guo, Chao, et al

Publish date:: October 1, 2017

Patients with acute myeloid leukemia (AML) between 60 and 85 years of age experienced a high complete remission rate after undergoing HLA-mismatched microtransplant, according to a study involving 185 individuals. Those aged 60 to 74 years experienced higher 1-year overall survival. Participants with newly-diagnosed AML who received microtransplant were divided into 4 age groups (60 to 64, 65 to 69, 70 to 74, and 75 to 85 years) and followed between 2005 and 2015. Among the results:

The overall complete remission rate was similar in the 4 groups, ranging between 70% and 79%.
1-year overall survival rates were 88%, 86%, 79%, and 52%, respectively.
2-year overall survival rates were 64%, 67%, 34%, and 15%, respectively.
1-year cumulative incidences of nonrelapse mortality were 10%, 0%, 3%, and 26%, respectively.
Nonrelapse mortality was 8% overall.
Median time to neutrophil recovery was 12 days after induction chemotherapy; it was 14 days for platelet recovery.

Citation:

Guo M, Chao N, Li J, et al. HLA-Mismatched microtransplant in older patients newly diagnosed with acute myeloid leukemia: Results from the Microtransplantation Interest Group. [Published online ahead of print September 14, 2017]. JAMA Oncol. doi:10.1001/jamaoncol.2017.2656.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release